NASDAQ:NRXS NeurAxis (NRXS) Stock Price, News & Analysis $2.67 +0.12 (+4.71%) (As of 12/29/2023 ET) Add Compare Share Share Today's Range$2.36▼$2.9650-Day Range$1.90▼$3.2752-Week Range$1.80▼$6.93Volume13,209 shsAverage Volume14,668 shsMarket Capitalization$14.12 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsSocial Media About NeurAxis Stock (NASDAQ:NRXS)NeurAxis, Inc. operates as a neuromodulation therapy device company in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome healthcare companies primarily hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.Read More NRXS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NRXS Stock News HeadlinesDecember 27, 2023 | americanbankingnews.comNeurAxis (NASDAQ:NRXS) Trading Up 12%December 20, 2023 | finanznachrichten.deNeurAxis, Inc. Issues Letter to Shareholders from Brian Carrico, President and Chief Executive OfficerDecember 31, 2023 | Behind the Markets (Ad)New Year's Sale: Get 12 Months of Stock Picks for $9.00Gear up for what's happening in the stock market in 2024. Our friends at Behind the Markets are offering an opportunity that is simply too good to pass up - 12-months of their best stock ideas for just $9.00. Don't sleep on this. December 20, 2023 | finance.yahoo.comNeurAxis, Inc. Issues Letter to Shareholders from Brian Carrico, President and Chief Executive OfficerNovember 21, 2023 | finanznachrichten.deNeurAxis, Inc.: NeurAxis Reports Third Quarter 2023 Financial ResultsNovember 21, 2023 | msn.comNeurAxis reports Q3 resultsNovember 20, 2023 | finance.yahoo.comNeurAxis Reports Third Quarter 2023 Financial ResultsNovember 15, 2023 | finance.yahoo.comNeurAxis Announces CareFirst BCBS Policy CoverageDecember 31, 2023 | Behind the Markets (Ad)New Year's Sale: Get 12 Months of Stock Picks for $9.00Gear up for what's happening in the stock market in 2024. Our friends at Behind the Markets are offering an opportunity that is simply too good to pass up - 12-months of their best stock ideas for just $9.00. Don't sleep on this. November 14, 2023 | msn.comNeurAxis secures $3M financing through preferred stock offeringNovember 14, 2023 | finance.yahoo.comNeurAxis Secures $3 Million FinancingNovember 8, 2023 | finance.yahoo.comNeurAxis Signs Exclusive Option Agreement with University of Michigan for Innovative Gastrointestinal DeviceNovember 5, 2023 | morningstar.comNeuraxis Inc NRXS Stock QuoteSeptember 26, 2023 | finance.yahoo.comNeurAxis Announces Results of Comparative Study of IB-Stim™ and Standard Medical Therapy in Adolescents with Functional Abdominal Pain DisordersSeptember 21, 2023 | finance.yahoo.comNeurAxis Reports Second Quarter 2023 Financial ResultsSeptember 13, 2023 | finance.yahoo.comNeurAxis to Present at the Gilmartin Group Emerging Growth ShowcaseSeptember 12, 2023 | stockhouse.comNeurAxis Announces Publication of Prospective Study Showing IB-Stim(TM) Improves Quality of Life of Adolescents with IBSSeptember 12, 2023 | msn.comEXCLUSIVE: NeurAxis' Nerve Field Stimulation Tech Shows Improved Quality of Life of Adolescents Patients With Irritable Bowel SyndromeSeptember 12, 2023 | finance.yahoo.comNeurAxis Announces Publication of Prospective Study Showing IB-Stim™ Improves Quality of Life of Adolescents with IBSSeptember 8, 2023 | finance.yahoo.comNeurAxis Highlights Current Commercial Insurance Coverage with BCBS Massachusetts, BCBS South Carolina, BCBS Nebraska, and Quartz WisconsinSeptember 8, 2023 | finance.yahoo.comExchange Listing Client, Neuraxis, Inc., Successfully Completes Its Initial Public Offering and NYSE ListingSeptember 8, 2023 | finance.yahoo.comGoldman Small Cap Research Publishes New Research Report on NeurAxis, Inc.September 8, 2023 | finance.yahoo.comNeurAxis Announces Positive University of Michigan IB-Stim™ Cost Effectiveness Study at ANMS 2023September 8, 2023 | finance.yahoo.comNeurAxis Announces Over $8 Million in IB-Stim™ RevenueSeptember 8, 2023 | finance.yahoo.comNeurAxis Highlights Two Independent Studies Showing Benefits of IB-Stim in Adolescents Involving the Gut MicrobiomeSeptember 8, 2023 | finance.yahoo.comNeurAxis Highlights Strength of its Board of DirectorsSeptember 8, 2023 | finance.yahoo.comNeurAxis Highlights Pediatric Post-Concussion Clinical StudySee More Headlines Receive NRXS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NeurAxis and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/20/2023Today12/31/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Electromedical equipment Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NRXS CUSIPN/A CIK1933567 Webneuraxis.com Phone(812) 689-0791FaxN/AEmployees17Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.43 Quick Ratio0.41 Sales & Book Value Annual Sales$2.68 million Price / Sales5.27 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares5,290,000Free FloatN/AMarket Cap$14.12 million OptionableNot Optionable BetaN/A 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Brian Carrico (Age 41)President, CEO & Director Comp: $373.58kDr. Adrian Miranda (Age 53)Chief Medical Officer, Senior VP of Science & Technology and Director Comp: $266.35kMr. Thomas Carrico (Age 66)Chief Regulatory Officer & Director Comp: $287.2kMr. Christopher Robin Brown D.D.S. (Age 69)Founder, Director of Innovation & Director Mr. Gary Peterson (Age 57)Founder, Director of Design & Engineering and Director Mr. John G. Seale CPA (Age 63)CFO & Teasurer Mr. Dan Clarence (Age 63)COO & Director More ExecutivesKey CompetitorsENDRA Life SciencesNASDAQ:NDRAHelius Medical TechnologiesNASDAQ:HSDTelectroCoreNASDAQ:ECORPrecision OpticsNASDAQ:POCIBioSig TechnologiesNASDAQ:BSGMView All CompetitorsInstitutional OwnershipStifel Financial CorpBought 25,710 shares on 11/13/2023Ownership: 0.516%View All Institutional Transactions NRXS Stock Analysis - Frequently Asked Questions Should I buy or sell NeurAxis stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NeurAxis in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" NRXS shares. View NRXS analyst ratings or view top-rated stocks. How have NRXS shares performed in 2023? NeurAxis' stock was trading at $6.00 at the beginning of 2023. Since then, NRXS shares have decreased by 55.5% and is now trading at $2.67. View the best growth stocks for 2023 here. How were NeurAxis' earnings last quarter? NeurAxis, Inc. (NASDAQ:NRXS) issued its earnings results on Monday, November, 20th. The company reported ($1.06) earnings per share for the quarter. The company earned $0.48 million during the quarter. When did NeurAxis IPO? (NRXS) raised $7 million in an IPO on Wednesday, August 9th 2023. The company issued 1,098,667 shares at $6.00 per share. When does NeurAxis' lock-up period expire? NeurAxis' lock-up period expires on Monday, February 5th. NeurAxis had issued 1,098,667 shares in its public offering on August 9th. The total size of the offering was $6,592,002 based on an initial share price of $6.00. After the end of NeurAxis' lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted. How do I buy shares of NeurAxis? Shares of NRXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NRXS) was last updated on 12/31/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeurAxis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.